报价延迟最少15分钟:2026/11/04 17:03 EST
盘后时段
|
||||
|
65.98 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
66
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.62/-4.92
|
|
企业价值
209.41M
|
| 资产负债 |
|
每股账面净值
14.69
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
19.39M
|
|
每股收益
0.38
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includesSGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease andother rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States. |
